Jia Ruan, MD, PhD, discusses the utility of molecular profiling in mantle cell lymphoma.
Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the utility of molecular profiling in mantle cell lymphoma (MCL).
Obtaining a patient's genetic mutation profile can be a useful risk-stratification tool, says Ruan. For example, TP53 mutations or deletions can inform a patient’s prognosis and likelihood of response to standard therapy.
Prospective studies using chemoimmunotherapy demonstrated less favorable survival data for patients with TP53 aberrations compared with patients who do not harbor TP53 aberrations, explains Ruan. Although chemoimmunotherapy may be offered to these patients, alternative options should be considered early on in cases of no response or early relapse.